About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Letrozole as a Treatment of Endometrial Cancer

NCT00997373·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of California, Davis

Age

40–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
Post menopausal status must be demonstrated
Signed informed consent

You may not be if

FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
Younger than 40 or postmenopausal status not established
Pregnant or breastfeeding

The record

StatusCompleted

PhaseNo phase

Taking part43

StartedOct 2009

UpdatedMay 30, 2017

Conditions

Endometrial Carcinoma

Where2

University of California Davis
Sacramento, California, United States
University of California, Davis
Sacramento, California, United States

Clareo Health | Letrozole as a Treatment of Endometrial Cancer